At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 36 enrolled
Drug / intervention
Methylphenidate Transdermal System +1 moredrug
Likely dose
Methylphenidate Transdermal System 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety/Tolerability of Methylphenidate Transdermal System (MTS) for Before-School Dysfunction in Children With Attention Deficit Hyperactivity Disorder (ADHD)
In Brief
A Phase 4 clinical trial evaluating Methylphenidate Transdermal System and Placebo for ADHD and Attention Deficit Hyperactivity Disorder. Completed, enrolled 36 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate the effectiveness of a medication skin patch called Methylphenidate Transdermal System (MTS). We will compare the MTS medicated patch to a placebo patch. We want to find out how well it treats ADHD during the early morning hours before a child leaves for school or summertime routines.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsADHD, Attention Deficit Hyperactivity Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2006
First PostedJan 2008
Primary CompletionDec 2008
TodayJul 2026
First PostedJan 4, 2008
Enrollment StartSep 1, 2006
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 18.5 years ago
Interventions
Methylphenidate Transdermal Systemdrug
Medication skin patch titrated to 20mg (at 10 mg and 20 mg doses)
Placebodrug
Placebo skin patch titrated to 20mg (at 10 mg and 20 mg doses)